C
23.08
0.14 (0.61%)
| Previous Close | 22.94 |
| Open | 23.06 |
| Volume | 260,143 |
| Avg. Volume (3M) | 1,380,484 |
| Market Cap | 2,836,817,920 |
| Price / Earnings (TTM) | 13.50 |
| Price / Earnings (Forward) | 10.22 |
| Price / Sales | 4.98 |
| Price / Book | 3.03 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | 36.91% |
| Operating Margin (TTM) | 44.81% |
| Diluted EPS (TTM) | 1.57 |
| Quarterly Revenue Growth (YOY) | 43.60% |
| Quarterly Earnings Growth (YOY) | 143.80% |
| Total Debt/Equity (MRQ) | 0.39% |
| Current Ratio (MRQ) | 6.14 |
| Operating Cash Flow (TTM) | 267.93 M |
| Levered Free Cash Flow (TTM) | 223.08 M |
| Return on Assets (TTM) | 18.59% |
| Return on Equity (TTM) | 29.11% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Catalyst Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
1.6
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 1.63 |
|
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.22% |
| % Held by Institutions | 83.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deerfield Management Company, L.P. | 30 Sep 2025 | 4,974,767 |
| Fundsmith Llp | 30 Sep 2025 | 3,363,807 |
| Royce & Associates Lp | 30 Sep 2025 | 2,034,965 |
| 52 Weeks Range | ||
| Median | 33.00 (42.98%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 07 Nov 2025 | 33.00 (42.98%) | Buy | 21.39 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |